The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation. (NCT06324201)
The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO™ System Use in Conjunction With VISITAG SURPOINT™Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation
🩺 Plain-English Summary (8th-Grade Level)
Observational, multi-center, non-randomized, post-market study. This is a nested sub-study of the REAL AF Registry. Consecutive symptomatic drug refractory paroxysmal atrial fibrillation (PAF) patients from the registry will be screened for enrollment, prospectively or retrospectively, to this sub-study per inclusion and exclusion criteria.
Who can join: Review the eligibility criteria below.
Location: Arrhythmia Institute at Grandview — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- Arrhythmia Institute at Grandview — Birmingham, Alabama
- Mobile Cardiology Associates — Mobile, Alabama
- Community Memorial Health System — Ventura, California
- Medical City - HCA — Aurora, Colorado
- Naples Community Hospital — Naples, Florida
- Sarasota Memorial Health — Sarasota, Florida
- Piedmont Healthcare — Atlanta, Georgia
- Norton Heart and Vascular Institute — Louisville, Kentucky
- The Brigham and Womens Hospital — Boston, Massachusetts
- Sparrow Clinical Research Institute — Lansing, Michigan
- Trinity Health-Michigan Heart — Ypsilanti, Michigan
- The Christ Hospital — Cincinnati, Ohio
- University of Cincinnati — Cincinnati, Ohio
- University of Pennsylvania (UPENN) — Philadelphia, Pennsylvania
- Allegheny Health — Pittsburgh, Pennsylvania
- Centra Health, Inc.dba Stroobants Cardiovascular Center — Lynchburg, Virginia
- Bon Secours Medical Group - Richmond Specialty Care — Richmond, Virginia
- Valley Health System — Winchester, Virginia
- Multicare Health Systems-Pulse Heart — Puyallup, Washington
- Franciscan Heart and Vascular Associates — Tacoma, Washington
- Mercy Health — Janesville, Wisconsin
📞 Contact the Study Coordinator
Phone: (615) 448-5770
Email: jmoss@hrcrs.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Paroxysmal Atrial Fibrillation
- Meditation and Education That is Nurse Delivered for Symptom Management in Paroxysmal Atrial Fibrillation (PAF) — Stanford, California
- ADVENT Post Approval Study — Mobile, Alabama
- Treatment of PAF With the Synaptic System — Phoenix, Arizona
- Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation — Birmingham, Alabama
- ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients — Jonesboro, Arkansas
- Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB) — New Hyde Park, New York
Explore by condition: All Paroxysmal Atrial Fibrillation clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.